Abstract A vaccine against viral hepatitis comprising: A. antigenic particles having a particle size in the range of 30 to 50 nanometers, said antigenic particles containing hepatitis B surface antigens; B. said antigen having less than 10 units of free antibody to hepatitis B surface antigens per 1,000 units of hepatitis B surface antigens; C. at least 5% of the particles of said vaccine in the size range of 30 to 50 nanometers containing the hepatitis B surface antigenic specificity(s) which have been termed "e-antigen"; D. said hepatitis B surface antigens, including e-antigens, being present in said vaccine in an amount sufficient to produce antibodies when introduced into a host animal, the balance being a medium which is physiologically acceptable, especially to humans and primates.
An antigenic mass effective against viral hepatitis comprising a solution of a physiologically acceptable medium substantially free of human serum proteins, said solution containing e-antigen, dissolved in said medium, said antigen being present in an amount sufficient, when introduced into a host animal, to effect formation of antibodies corresponding thereto, said antigenic mass obtained from the serum of a chronic HBsAg carrier whose serum contains e-antigen, said antigenic mass being substantially free of combined anti-e antibody.
Claim 2
Dependent Claim
76 words
An antigenic mass effective against viral hepatitis comprising a solution of a physiologically acceptable medium substantially free of human serum proteins, said solution containing e-antigen, dissolved in said medium, said antigen being present in an amount sufficient, when introduced into a host animal, to effect formation of antibodies corresponding thereto, said antigenic mass obtained from the serum of a chronic HBsAg carrier whose serum contains e-antigen, said antigenic mass being substantially free of combined anti-e antibody.